Tony Milici, MD, PhD, GeneThera’s chairman, said in the statement that the company will launch phase 2 clinical trials shortly. “Our goal is to take the vaccine to market as soon as possible,” he added. Brett Finlay, a microbiologist at the University of British Columbia whose research led to development of the vaccine, said in an Oct 27 Bioniche press release, “If we block the colonization of cows by O157, we basically decrease the number that humans are exposed to, and thus, dropping disease levels in humans.” Bioniche is also positioning itself to market the vaccine to cattle producers in the United States, according to a previous report. In February, the US Department of Agriculture (USDA) notified the company that the latest data on the vaccine met its “expectation of efficacy” standard, which allowed the company to pursue a conditional US license. The vaccine contains live attenuated bacteria developed by Edgar Boedeker, an internal medicine professor at UNM, and Chengru Zhu, formerly of UNM and now chief of environmental microbiology at the Maryland Department of Health, according to a GeneThera statement. The vaccine is designed to inhibit the carriage and shedding of enterohemorrhagic E coli such as O157:H7. ‘A missing link’Bill Clark, a nephrologist at the London Health Sciences Centre in London, Ont., said that an E coli O157:H7 vaccine isn’t a firewall against food contamination, according to an Oct 28 report from the Canadian Broadcasting Corporation (CBC). “I’m not sure any one solution will do it, and I certainly think people still have to be very careful with their food practices,” he told the CBC. Nov 3, 2008 (CIDRAP News) – Bioniche Life Sciences, based in Belleville, Ont., announced recently that it received full approval from the Canadian Food Inspection Agency (CFIA) to market the world’s first vaccine to reduce Escherichia coli O157:H7 shedding by cattle, a measure that could decrease contamination in meat and produce. E coli O157:H7 doesn’t sicken cattle but is potentially fatal to humans. It produces a toxin that causes diarrhea, often bloody, but usually no fever. Though most patients with E coli O157:H7 infections recover in 5 to 10 days, 2% to 7% develop hemolytic uremic syndrome, a potentially fatal form of kidney failure. The vaccine, called Econiche, will be produced at Bioniche’s Belleville facility, which is undergoing a $25 million expansion. The company said vaccine supplies would be limited during the expansion period. Oct 27 Bioniche press release about vaccine’s approval Oct 17 Bioniche press release about study of vaccine US company eyes cattle vaccineOn the same day Bioniche announced it had received full Canadian approval, a US company, GeneThera, Inc, based in Wheat Ridge, Colo., announced that it had signed an agreement with the University of New Mexico’s (UNM’s) technology transfer arm to license and distribute a cattle E coli vaccine developed at the UNM Health Sciences Center. Smith DR, Moxley RA, Peterson RE, et al. A two-dose regimen of a vaccine against Escherichia coli O157:H7 type III secreted proteins reduced environmental transmission of the agent in a large-scale commercial beef feedlot clinical trial. Foodborne Pathogens and Disease 2008 Oct 1;5(5):589-98 [Abstract] Kym Anthony, a specialty beef producer in Clarksburg, Ont., said in the Bioniche press release that he has been using the vaccine over the past year under a conditional Canadian permit. “We’ve been trying to do our part to be an industry leader in food safety. The E coli vaccine fits into that,” Anthony said. “It’s been a missing link in the industry so far.” See also: The company said the vaccine could also be used in livestock at petting zoos and agricultural expositions to reduce bacterial transmission to humans. However, some producers may find the cost prohibitive. Rick Holley, a professor of food safety and microbiology at the University of Manitoba, told the CBC, “So long as these organisms don’t make the animals sick, you’re not going to see a great deal of incentive to move toward prevention.” The company did not list a cost for the vaccine, but officials previously told CIDRAP News that a course of the vaccine would likely cost less than $10 per head of cattle. As approved by the CFIA, the course involves three doses, but a study published in the October issue of Foodborne Pathogens and Disease showed that a two-dose regimen reduced the probability of environmental transmission of E coli O157:H7 within a large-scale cattle feeding operation.
Renders of The Deck at Signature Broadbeach.SJB Interiors designed The Deck.“The Deck’s shared spaces encourage relaxation and interaction with neighbours and friends, while responding to the building’s physical form and coastal location, creating a series of recreational and tranquil spaces,” SJB Interiors director Ljiljana Gazevic said.“Signature Broadbeach has been designed to celebrate the unique lifestyle that represents living on the Gold Coast.”Signature features a collection of one, two and three-bedroom residences across 35 levels.Apartments start from $475,000. The pool at Signature Broadbeach.The resident’s lounge and private dining room integrate with the pool area and provides intimate spaces for formal and informal entertaining.More from news02:37International architect Desmond Brooks selling luxury beach villa18 hours ago02:37Gold Coast property: Sovereign Islands mega mansion hits market with $16m price tag2 days agoThe outdoor barbecue and teppanyaki grill area are perfect for casual poolside dining, while a cinema and gym provide an outlet for residents looking to relax, unwind or exercise.“No other residential development in this market offers the extent or quality amenity of Signature, which was inspired by the amenity of luxury hotels,” Mr Pyke said. Renders of The Deck at Signature Broadbeach. Renders of The Deck at Signature Broadbeach.WELCOME to a new level of living at Broadbeach.Little Projects’ development director Leighton Pyke said The Deck at Signature Broadbeach was designed to complement its beachside location.Exclusively for residents, a 50m infinity edge pool is the centrepiece of the space. Renders of The Deck at Signature Broadbeach.